Venmax Drugs and Pharmaceuticals
Venmax Drugs and Pharmaceuticals Share Price Chart
Venmax Drugs and Pharmaceuticals last traded at ₹14.00 (2026-10-13). Over the past month the stock moved -6.5%, three months the stock moved -39.6%, year the stock moved -48.8%. Its closing range over 52 weeks is ₹13.93 – ₹29.71, with the latest close 52.9% below the high.
Closing prices up to 2026-10-13.
About Venmax Drugs and Pharmaceuticals
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
Business Overview:[1] a) VDPL is focused on establishing chain of Medical Stores with a brand name Ananya Pharma under the Venmax Drugs & Pharma Ltd, with the backing support of Formulations plant (Suzichem Labs). Currently, it has established 3 Shops & planning to expand them to 50 numbers around Hyderabad. b) The company is developing oncology products in R&D. It is planning to establish a manufacturing UNIT with cGMP facility at Pharma Cluster at Hyderabad, to meet the export demand.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Venmax Drugs and Pharmaceuticals reported sales of ₹2.48 crore (+105.0%) and net profit of ₹0.12 crore (+200.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 2.48 | 0.12 | 4.84 | 0.12 | 0.10 |
| Mar 2026 | 3.94 | 0.02 | 0.51 | 0.11 | 0.09 |
| Dec 2025 | 1.55 | -0.03 | -1.94 | 0.03 | 0.04 |
| Sep 2025 | 1.32 | 0.05 | 3.79 | 0.02 | 0.02 |
| Jun 2025 | 1.21 | 0.04 | 3.31 | 0.04 | 0.08 |
| Mar 2025 | 0.33 | -0.24 | -72.73 | 0.78 | 1.49 |
| Dec 2024 | 0.20 | -0.49 | -245.00 | -0.50 | -0.95 |
| Sep 2024 | 0.17 | -0.30 | -176.47 | -0.30 | -0.57 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | – | – | – | +1110.0% | +676.5% | +675.0% | +1093.9% | +105.0% |
| Operating profit growth | – | – | – | – | – | – | – | +200.0% |
| Net profit growth | – | -1766.7% | +1460.0% | +300.0% | – | – | -85.9% | +200.0% |
| EPS growth | – | -1683.3% | +1390.0% | +300.0% | – | – | -94.0% | +25.0% |
| OPM % | -176.5% | -245.0% | -72.7% | 3.3% | 3.8% | -1.9% | 0.5% | 4.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Venmax Drugs and Pharmaceuticals reported sales of ₹8.02 crore (+890.1%) and net profit of ₹0.25 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 8.02 | 0.12 | 1.50 | 0.25 | 0.22 |
| Mar 2025 | 0.81 | -1.06 | -130.86 | -0.01 | -0.02 |
| Mar 2024 | 0.00 | -0.11 | – | 0.06 | 0.11 |
| Mar 2023 | 0.00 | -0.19 | – | 0.23 | 0.44 |
| Mar 2022 | 0.00 | -0.12 | – | 1.85 | 3.53 |
| Mar 2021 | 0.17 | -0.33 | -194.12 | -0.16 | -0.31 |
| Mar 2020 | 0.47 | -0.25 | -53.19 | -0.27 | -0.52 |
| Mar 2019 | 0.15 | -0.23 | -153.33 | -0.24 | -0.46 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | – | +213.3% | -63.8% | -100.0% | – | – | – | +890.1% |
| Operating profit growth | – | – | – | – | – | – | – | – |
| Net profit growth | – | – | – | – | -87.6% | -73.9% | -116.7% | – |
| EPS growth | – | – | – | – | -87.5% | -75.0% | -118.2% | – |
| OPM % | -153.3% | -53.2% | -194.1% | – | – | – | -130.9% | 1.5% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Venmax Drugs and Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Venmax Drugs&Pharma reports Profit after tax of Rs 1.18 Mln, in the June 2026 quarter
Frequently Asked Questions
What is the share price of Venmax Drugs and Pharmaceuticals today?
Venmax Drugs and Pharmaceuticals shares were last quoted at ₹14.00 (-2.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Venmax Drugs and Pharmaceuticals?
Venmax Drugs and Pharmaceuticals has a price-to-earnings (P/E) ratio of 46.87 and a price-to-book (P/B) ratio of 1.16. The industry P/E is 53.33.
What is the 52-week high and low of Venmax Drugs and Pharmaceuticals?
The 52-week high of Venmax Drugs and Pharmaceuticals is ₹31.49 and the 52-week low is ₹12.71.
What is the market cap of Venmax Drugs and Pharmaceuticals?
The market capitalisation of Venmax Drugs and Pharmaceuticals is about ₹13.17 crore.
How did Venmax Drugs and Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Venmax Drugs and Pharmaceuticals reported sales of ₹2.48 crore (+105.0%) and net profit of ₹0.12 crore (+200.0%), compared with the same quarter last year.
Is Venmax Drugs and Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Venmax Drugs and Pharmaceuticals has 3-year profit growth of 3.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Venmax Drugs and Pharmaceuticals?
Promoters hold about 10.46% of Venmax Drugs and Pharmaceuticals.
Which sector does Venmax Drugs and Pharmaceuticals belong to?
Venmax Drugs and Pharmaceuticals belongs to the Pharmaceuticals sector.